Biogenvs.Regeneron
BIIB vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 2.6× larger than Biogen by market cap; Regeneron trades at the lower P/E (19.0 vs 37.2); year to date, Biogen leads (+23.9% vs +7.3%).
Side by side
| BIIB | REGN | |
|---|---|---|
| Market cap | $31B | $82.2B |
| Price | $220.77 | $833.56 |
| Today | +1.2% | +0.6% |
| Return YTD | +23.9% | +7.3% |
| Return 1Y | +56.6% | +40.5% |
| P/E | 37.2 | 19.0 |
| P/S | 3.1 | 5.3 |
| P/B | 1.6 | 2.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More BIIB & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and REGN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →